These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19439020)

  • 21. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.
    Ehrlich HJ; Müller M; Fritsch S; Zeitlinger M; Berezuk G; Löw-Baselli A; van der Velden MV; Pöllabauer EM; Maritsch F; Pavlova BG; Tambyah PA; Oh HM; Montomoli E; Kistner O; Noel Barrett P
    J Infect Dis; 2009 Oct; 200(7):1113-8. PubMed ID: 19712040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative study of immunogenicity and safety of domestic influenza vaccines].
    Yao J; Li Q; Xu Q; Feng CF; Lu YM; Xu BQ; Lu Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):735. PubMed ID: 15555412
    [No Abstract]   [Full Text] [Related]  

  • 23. The effect of osteopathic manipulative treatment on immune response to the influenza vaccine in nursing homes residents: a pilot study.
    Noll DR; Degenhardt BF; Stuart MK; Werden S; McGovern RJ; Johnson JC
    Altern Ther Health Med; 2004; 10(4):74-6. PubMed ID: 15285277
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
    Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A
    J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influenza virus-like particle vaccines.
    Haynes JR
    Expert Rev Vaccines; 2009 Apr; 8(4):435-45. PubMed ID: 19348559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative influenza vaccines made by insect cells.
    Krammer F; Grabherr R
    Trends Mol Med; 2010 Jul; 16(7):313-20. PubMed ID: 20570562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunogenicity and safety of influenza split vaccine].
    Dong JH; Chang WH; Tian XP
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Mar; 30(3):310-1. PubMed ID: 19642397
    [No Abstract]   [Full Text] [Related]  

  • 28. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel emulsion adjuvant increases the immunogenic responses and protective efficacy of an inactivated influenza vaccine in BALB/c mice.
    Wang S; Ke CW; Zou LR; Jing Z; Xie GX; Li X
    Intervirology; 2009; 52(5):252-7. PubMed ID: 19622895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial.
    Chiu SS; Chan KH; Tu W; Lau YL; Peiris JS
    Vaccine; 2009 Jul; 27(35):4834-9. PubMed ID: 19523908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial.
    Beran J; Vesikari T; Wertzova V; Karvonen A; Honegr K; Lindblad N; Van Belle P; Peeters M; Innis BL; Devaster JM
    J Infect Dis; 2009 Dec; 200(12):1861-9. PubMed ID: 19909082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. M2e-based universal influenza A vaccine.
    Fiers W; De Filette M; El Bakkouri K; Schepens B; Roose K; Schotsaert M; Birkett A; Saelens X
    Vaccine; 2009 Oct; 27(45):6280-3. PubMed ID: 19840661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pandemic vaccine enters clinical trials.
    Willyard C
    Nat Med; 2009 Sep; 15(9):978. PubMed ID: 19734857
    [No Abstract]   [Full Text] [Related]  

  • 34. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children.
    Breiman RF; Brooks WA; Goswami D; Lagos R; Borja-Tabora C; Lanata CF; Londoño JA; Lum LC; Rappaport R; Razmpour A; Walker RE; Gruber WC; Forrest BD
    Vaccine; 2009 Sep; 27(40):5472-9. PubMed ID: 19616493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 May; 58(19):521-4. PubMed ID: 19478718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influenza control in the 21st century: Optimizing protection of older adults.
    Monto AS; Ansaldi F; Aspinall R; McElhaney JE; Montaño LF; Nichol KL; Puig-Barberà J; Schmitt J; Stephenson I
    Vaccine; 2009 Aug; 27(37):5043-53. PubMed ID: 19559118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
    Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
    Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Vaccine: its application and development].
    Yamane N
    Rinsho Byori; 1986 Jan; 34(1):31-7. PubMed ID: 2422411
    [No Abstract]   [Full Text] [Related]  

  • 39. [Prevention of grippe. Principles of vaccine manufacture].
    Brangier J
    Soins; 1982 Oct; (391):19-21. PubMed ID: 6925315
    [No Abstract]   [Full Text] [Related]  

  • 40. The European CHMP criteria for influenza vaccine immunogenicity cannot be improved by the use of confidence intervals.
    Nauta JJ; de Bruijn IA
    Vaccine; 2006 Nov; 24(44-46):6643-4. PubMed ID: 16797109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.